Ⅰ期肺腺癌中LAT1的表达及临床意义

Expression of LAT1 in stage Ⅰ lung adenocarcinoma and its clinical significance

目的探讨L型氨基酸转运载体1(L-type amino acid transporter 1,LAT1)在Ⅰ期肺腺癌组织中表达的预后意义。方法回顾性分析141例经外科治疗的Ⅰ期肺腺癌患者临床病理资料,采用免疫组化MaxVision法检测LAT1和Ki-67的表达,分析它们与患者的临床病理特征及预后的关系,并检测了LAT1和Ki-67表达的关系。结果 141例Ⅰ期肺腺癌组织中LAT1和Ki-67表达阳性率分别为67.4%和56.0%。LAT1表达与疾病分期(P=0.002)、胸膜侵犯(P=0.038)、肿瘤复发转移(P=0.003)及Ki-67表达有相关性(P=0.037)。单因素分析提示:肿瘤大小(P=0.017)、临床分期(P=0.000)、脉管侵犯(P=0.013)、复发转移(P=0.000)、LAT1(P=0.000)及Ki-67表达(P=0.017)为预后相关因素(P<0.05);而Cox多因素回归分析表明,临床分期(P=0.045)、复发转移(P=0.013)、LAT1表达(P=0.029)为独立预后因素。结论 LAT1的表达与Ⅰ期肺腺癌的临床分期、复发转移、预后以及癌细胞增殖密切相关,LAT1高表达提示预后不良。

Purpose To evaluate the prognostic value of L-type amino acid transporter 1 （ LAT1 ） expression in patients with stage I pulmonary adenocarcinoma. Methods A total of 141 consecutive patients with pathologic stage I pulmonary adenocarcinoma were retrospectively reviewed. The expression of LAT1 and Ki-67 was evaluated immunohistochemically and correlated with the prognosis of pa- tients with complete resection of the tumor. Results The positive rates of LAT1 and Ki-67 expression were 67.4% and 56. 0% , respectively. LAT1 expression was signifieantly correlated with disease stage （P = 0. 002 ）, pleural invasion （P = 0. 038 ） recurrence and/or metastasis （ P = 0. 003 ） and Ki-67 expression （ P = 0. 037 ）. Univariate analysis disclosed that tumor size （ P = 0. 017 ） , and clinical stage （P =0. 000）, vascular invasion （P =0. 013）, recurrence and/or metastasis （P =0. 000）, the expression of LAT （P = 0. 000） and Ki-67 （P = 0. 017 ） in the tumor were significantly prognostic factors. The Cox regression analysis demonstrated that clinical stage （ P = 0. 045 ） , recurrence and/or metastasis （ P = 0. 013 ） and the expression of LAT1 （ P = 0. 029 ） were significant independent factors to predict a poor prognosis. Conclusions The overexpression of LAT1 is a pathological factor to predict the prognosis of patients with stage I pulmonary adenocarcinoma.